178 related articles for article (PubMed ID: 31175351)
1. Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.
Gan Q; Joseph CT; Guo M; Zhang M; Sun X; Gong Y
Am J Clin Pathol; 2019 Sep; 152(4):495-501. PubMed ID: 31175351
[TBL] [Abstract][Full Text] [Related]
2. Utility of NKX3.1 immunohistochemistry in the differential diagnosis of seminal vesicles versus prostatic tissue in needle biopsy.
Pitra T; Pivovarcikova K; Alaghehbandan R; Compérat EM; Hora M; Rogala J; Slisarenko M; Michal M; Hes O
Ann Diagn Pathol; 2020 Dec; 49():151644. PubMed ID: 33126153
[TBL] [Abstract][Full Text] [Related]
3. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males.
Abouhashem NS; Salah S
Pathol Res Pract; 2020 Oct; 216(10):153221. PubMed ID: 32979741
[TBL] [Abstract][Full Text] [Related]
5. Immunostaining for thyroid transcription factor-1 on fine-needle aspiration specimens of lung tumors: a comparison of direct smears and cell block preparations.
Liu J; Farhood A
Cancer; 2004 Apr; 102(2):109-14. PubMed ID: 15098255
[TBL] [Abstract][Full Text] [Related]
6. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
Jia L; Jiang Y; Michael CW
Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
[TBL] [Abstract][Full Text] [Related]
7. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.
Tsai H; Morais CL; Alshalalfa M; Tan HL; Haddad Z; Hicks J; Gupta N; Epstein JI; Netto GJ; Isaacs WB; Luo J; Mehra R; Vessella RL; Karnes RJ; Schaeffer EM; Davicioni E; De Marzo AM; Lotan TL
Clin Cancer Res; 2015 Dec; 21(24):5619-29. PubMed ID: 26246306
[TBL] [Abstract][Full Text] [Related]
9. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
10. Metastatic small-cell carcinoma of the prostate diagnosed by fine-needle aspiration biopsy.
Caraway NP; Fanning CV; Shin HJ; Amato RJ
Diagn Cytopathol; 1998 Jul; 19(1):12-6. PubMed ID: 9664178
[TBL] [Abstract][Full Text] [Related]
11. Prostatic adenocarcinoma metastases mimicking small cell carcinoma on fine-needle aspiration.
Parwani AV; Ali SZ
Diagn Cytopathol; 2002 Aug; 27(2):75-9. PubMed ID: 12203872
[TBL] [Abstract][Full Text] [Related]
12. Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration.
Renshaw AA; Granter SR
Diagn Cytopathol; 2000 Sep; 23(3):199-201. PubMed ID: 10945910
[TBL] [Abstract][Full Text] [Related]
13. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
14. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
15. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
16. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
[TBL] [Abstract][Full Text] [Related]
18. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
19. A novel case of NKX3.1-positive metastatic cutaneous prostate cancer.
Wong JK; Minni JP; Nowak MA
Dermatol Online J; 2018 Oct; 24(10):. PubMed ID: 30677815
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]